WATER ISLAND CAPITAL LLC's Masimo Corp(MASI) Holding History
WATER ISLAND CAPITAL LLC holds 194,197 shares of Masimo Corp (MASI), valued at $34.54 million, constituting 4.07% of its portfolio. The initial purchase was in Q1 2026 at an average price of $156.95 per share. Based on the current price of $178.81, the firm has an estimated gain of $4.25 million, or 13.93%.
Pentwater discloses 3.18M-share stake in Masimo (MASI)
Pentwater Capital Management LP has disclosed a beneficial ownership of 3,176,000 shares in Masimo Corp. (MASI), representing a 6.1% stake in the company. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment. The filing specifies that Pentwater Capital Management LP and Matthew Halbower, the sole shareholder of the investment manager's general partner, share both voting and dispositive power over these shares.
[SCHEDULE 13G] MASIMO CORP Passive Investment Disclosure (>5%)
Barclays PLC has filed a Schedule 13G for Masimo Corp (MASI), reporting beneficial ownership of 2,892,262 shares, which represents 5.54% of the common stock as of March 31, 2026. The filing indicates that Barclays PLC holds sole voting and dispositive power over these shares and lists several Barclays subsidiaries as relevant entities. The purpose of the investment is passive, with no intention to change or influence the control of the issuer.
Joe Kiani holds 3.66M shares of Masimo (NASDAQ: MASI), cites disputed awards
Joe Kiani reports beneficial ownership of 3.66 million shares (6.5%) of Masimo Corporation (NASDAQ: MASI), a figure that includes several disputed equity awards. Kiani contends that Masimo has refused to process certain exercises and issue shares related to these awards, leading to litigation in the Delaware Court of Chancery. His beneficial ownership calculation, based on 52,365,808 shares outstanding as of April 4, 2026, explicitly includes these contested awards for transparency, despite them not yet being issued by the company.
Swedbank AB Sells 8,000 Shares of Masimo Corporation $MASI
Swedbank AB has reduced its stake in Masimo Corporation by selling 8,000 shares, bringing its total holding to 59,500 shares valued at approximately $7.74 million. Despite increased institutional investment from several other firms, analyst sentiment for Masimo remains cautious, with an average "Hold" rating and a target price of $180.40 following recent downgrades. Masimo (NASDAQ:MASI) stock opened at $178.31, with a market capitalization of $9.34 billion.
MASI Price Today: Masimo Corporation Stock Price, Quote & Chart | MEXC
This article provides current stock information for Masimo Corporation (MASI), trading at $178.28 with a -0.11% change from its previous close. It details key market data, recent price movements over various periods, and how to buy MASI stock on MEXC. The report also includes company information, sector classification, market valuation, P/E ratio, and answers frequently asked questions about its financial performance and dividend policy.
Comerica Bank Lowers Stock Holdings in Masimo Corporation $MASI
Comerica Bank significantly reduced its stake in Masimo Corporation (NASDAQ:MASI) by 94.8% in the fourth quarter, selling over 221,000 shares. Despite this reduction, several other major institutional investors, including Viking Global and UBS Group AG, increased their positions, with institutional ownership of Masimo standing at approximately 85.96%. Masimo currently trades around $178.50, has a market cap of $9.35 billion, and analysts generally have a "Hold" rating with a consensus target price of $180.40.
Masimo Shareholder Notice
Faruqi & Faruqi, LLP is investigating potential claims against Masimo Corporation (NASDAQ: MASI) and reminds investors of the October 23, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Masimo misled investors about its sales pipeline and revenue guidance for fiscal 2023, leading to a significant stock price drop following their Q2 2023 earnings announcement. Investors who suffered losses exceeding $100,000 between February 28, 2023, and July 17, 2023, are encouraged to contact the firm.
Wilson Asset Management International PTY Ltd. Increases Stock Position in Masimo Corporation $MASI
Wilson Asset Management International PTY Ltd. significantly increased its stake in Masimo Corporation (NASDAQ:MASI) by 44.8% in the fourth quarter, bringing its total holding to 39,437 shares valued at approximately $5.13 million. Despite substantial institutional ownership at 85.96%, analyst sentiment for Masimo remains cautious, with a "Reduce" consensus rating and a target price of $181.17, as the stock trades near its one-year high. Masimo, a medical technology company specializing in noninvasive monitoring solutions, has a market cap of $9.32 billion.
Masimo Corp 1Q 2026: Revenue $403.6M, Net income $57.1M, EPS $1.09— 10-Q Summary
Masimo Corp reported strong first-quarter 2026 results, with revenue increasing by 8.5% to $403.6 million and a significant turnaround in net income, reaching $57.1 million compared to a loss in the prior year. Diluted EPS rose to $1.09. The growth was primarily driven by higher consumables and service sales, along with strategic developments including the sale of its non-healthcare Sound United business and a merger agreement with Danaher.
Masimo (MASI) CHRO nets RSU shares after tax-withholding share disposition
Masimo's Chief Human Resources Officer, Elisabeth A. Hellmann, reported the vesting of 335 restricted stock units (RSUs) on April 21, 2026. In connection with this, 121 shares were withheld by the company for tax obligations at $178.43 per share. Following these routine transactions, Hellmann now holds 214 shares of common stock and 1,005 remaining RSUs.
Masimo (MASI) chair exercises 1,225 RSUs and receives 1,119-unit grant
Masimo Corp's Chairman of the Board, Michelle Brennan, reported recent equity compensation activity. She exercised 1,225 restricted stock units (RSUs) into common shares, increasing her direct holdings to 8,543 shares. Additionally, Brennan received a new grant of 1,119 RSUs, which will vest on the earlier of one year from the grant date or the next annual stockholders meeting.
Vanguard Group Inc. Sells 461,225 Shares of Masimo Corporation $MASI
Vanguard Group Inc. reduced its stake in Masimo Corporation (NASDAQ:MASI) by 9.6% in the fourth quarter, selling 461,225 shares. Despite this, Vanguard remains a significant shareholder, owning 4,348,786 shares valued at $565.6 million. Other institutional investors have shown mixed activity, with some increasing and others decreasing their holdings in the medical equipment provider.
Masimo Corporation $MASI Shares Purchased by UBS Group AG
UBS Group AG significantly increased its stake in Masimo Corporation (NASDAQ:MASI) by 252.9% in the fourth quarter, acquiring an additional 429,474 shares to own a total of 599,274 shares worth $77.94 million. Other institutional investors like Royal Bank of Canada and AQR Capital Management LLC also increased their positions. Despite these purchases, Wall Street analysts have issued a mixed outlook, with an average rating of "Reduce" and a consensus target price of $181.17, although some have maintained or raised their ratings.
BlackRock (MASI) holds 116,871 shares of Masimo — 0.2% stake
BlackRock Portfolio Management LLC has reported a passive beneficial ownership of 116,871 shares in Masimo Corp (MASI), representing a 0.2% stake. This information is detailed in an amended Schedule 13G/A filing dated April 30, 2026, which indicates BlackRock holds sole voting power over 94,486 shares and sole dispositive power over all 116,871 shares. This filing is considered a routine institutional report due to the stake being below 5%.
M&T Bank Corp Purchases 6,578 Shares of Masimo Corporation $MASI
M&T Bank Corp significantly increased its stake in Masimo Corporation by 218.8% in Q4, acquiring an additional 6,578 shares to hold a total of 9,585 shares valued at approximately $1.247 million. This move is part of a broader trend of institutional investors raising their positions in Masimo, with institutional ownership currently at 85.96%. Despite strong institutional interest, analysts largely maintain a "Hold" or "Reduce" rating on the stock, with a consensus target price of $181.17.
Masimo (MASI) Study Shows High Accuracy of Pulse Oximetry in Neo
A recent study by Masimo (MASI) published results highlighting the high accuracy and reliability of its SET pulse oximetry technology for critically ill newborns, demonstrating strong performance across diverse populations without discrepancies based on skin pigmentation. Despite the positive technological advancements, the company's stock shows a high valuation with a P/S ratio of 6.33 and recent insider selling, which investors should consider alongside its strong GF Score™ of 87/100. The study reinforces Masimo's leadership in healthcare technology, but financial metrics and insider sentiment warrant careful research.
Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study – Company Announcement - FT.com
A new study, NeoPODS, confirmed the accuracy of Masimo SET® pulse oximetry in hospitalized newborns across all skin tones, showing less than 1% overall statistical bias and no clinically significant skin pigmentation-related discrepancies. The NIH-funded study found no occult hypoxemia in Black or Hispanic neonates, reinforcing the device's equitable performance in critical care settings. This research adds to existing evidence supporting Masimo SET®'s reliability under challenging real-world conditions for diverse patient populations.
Delaware Applies Moelis Amendment to Enforce Forum Selection in Stockholder Employment Agreement over Corporation’s Bylaw
The Delaware Court of Chancery recently ruled that a non-Delaware forum selection clause in a CEO's employment agreement superseded the corporation's bylaw mandating litigation in Delaware, even for fiduciary duty claims. This decision, based on the Moelis Amendment (8 Del. C. § 122(18)), has significant implications for Delaware corporations, particularly those with stockholder executives, as it validates non-Delaware forums for internal affairs disputes when established via stockholder agreements. Corporations are advised to review their existing agreements to avoid inadvertently overriding Delaware-only forum selection bylaws and consider internal affairs carveouts in future contracts.
Masimo (MASI) Proxy Filing Summary
Masimo's Board has unanimously approved an acquisition by Danaher for $180 per share, with the transaction expected to close in the second half of 2026. Masimo will operate as a standalone unit within Danaher's Diagnostics segment. Shareholders will vote on the proposed all-cash merger and related executive compensation at a forthcoming meeting.
Masimo Corporation $MASI Shares Bought by Cwm LLC
Cwm LLC significantly increased its stake in Masimo Corporation (NASDAQ:MASI) during Q4, boosting its holdings by 2,045.3% to 18,535 shares valued at approximately $2.41 million. Despite this institutional buying, Masimo has received multiple downgrades from research firms, resulting in a consensus "Reduce" rating and an average price target of $181.17. The company's stock currently trades around $178.63, with mixed valuation metrics including a negative P/E ratio.
Masimo to supplement proxy after shareholder suits; merger terms unchanged
Masimo announced it will voluntarily supplement its definitive proxy statement for the Danaher merger following several shareholder lawsuits, though the merger consideration and meeting timeline remain unchanged. The lawsuits allege the original proxy is incomplete, and while Masimo denies these claims, it will add disclosures to reduce litigation risk and avoid potential delays to the merger. The Board continues to recommend shareholders vote FOR the merger.
[8-K] MASIMO CORP Reports Material Event
MASIMO CORP (MASI) filed an 8-K report detailing a material event related to its pending merger with Danaher Corporation. The report provides supplemental disclosures to its definitive proxy statement, addressing stockholder litigation and demand letters concerning the merger. Masimo maintains that its disclosures comply with applicable law, but has supplemented the proxy to mitigate risks of delay to the merger and to minimize litigation costs, without admitting wrongdoing.
Masimo (MASI) Proxy Filing Summary
Masimo has agreed to be acquired by Danaher for $180.00 per share, operating as a standalone unit within Danaher's Diagnostics segment. This acquisition aims to strengthen Danaher's acute care offerings and expand Masimo's monitoring technologies globally. The transaction is contingent on shareholder and regulatory approvals, with shareholders set to vote on the merger and related executive compensation.
Masimo Founder Kiani Gets Severance Dispute Sent to California
Masimo Corp. founder Joe Kiani successfully moved his severance dispute with the biotech company to California, where he originally filed suit. A Delaware court rejected Masimo's attempt to keep the litigation in the Chancery Court, where the company had sought to invalidate Kiani's employment agreement. Kiani is seeking hundreds of millions in severance after losing control of the company to an activist hedge fund.
Masimo Founder Kiani Gets Severance Dispute Sent to California
Masimo Corp. founder Joe Kiani has successfully moved his severance dispute with the biotech company from Delaware back to California. Kiani is seeking hundreds of millions in severance after losing control of the company to an activist hedge fund, with a Delaware judge rejecting Masimo's attempt to litigate there and invalidate his employment agreement. This decision allows the legal battle over his $450 million severance claim to proceed in California, where he initially filed the lawsuit.
DHR Reports Strong Q1 Revenue and Plans Masimo Acquisition
Danaher Corp (NYSE: DHR) reported Q1 revenue of $6 billion, meeting market expectations, and announced plans to acquire Masimo Corporation. The company's GF Score of 80 indicates strong financial health despite insider selling activity. This acquisition aims to enhance Masimo's operations using Danaher's Digital Biology Solutions and global infrastructure.
Masimo Corporation (NASDAQ:MASI) Receives Consensus Rating of "Reduce" from Brokerages
Nine brokerages have issued a consensus rating of "Reduce" for Masimo Corporation (NASDAQ:MASI), with one analyst recommending "sell" and eight recommending "hold." The average 12-month target price is $181.17, indicating limited upside as the stock currently trades near its 52-week high. Institutional investors own a significant 85.96% of the company's stock.
13,196 Shares in Masimo Corporation $MASI Bought by Lecap Asset Management Ltd.
Lecap Asset Management Ltd. has acquired 13,196 shares of Masimo Corporation (NASDAQ:MASI) in the fourth quarter, totaling approximately $1.716 million. Despite this new institutional investment, the consensus analyst rating for Masimo is "Reduce" with a target price of $181.17, following several recent downgrades. Masimo is currently trading near its 52-week high, has a market cap of $9.58 billion, and is largely owned by institutional investors.
Masimo's Appeal Rejection, M5 Chip Push, China Smartphone Growth, Foldable iPhone: This Week In Appleverse
Apple Inc. experienced a dynamic week with key developments across legal, technological, and market sectors. The company secured a legal victory as the U.S. International Trade Commission rejected Masimo's appeal to reinstate an Apple Watch import ban. Apple is also advancing its edge AI capabilities with the M5 chip series, while defying a smartphone slump in China with significant growth.
Sumitomo Mitsui Trust Group Inc. Trims Stock Position in Masimo Corporation $MASI
Sumitomo Mitsui Trust Group Inc. significantly reduced its stake in Masimo Corporation, selling 96.3% of its shares in Q4 2025, leaving 14,572 shares valued at $1.895 million. This follows a cooling in analyst sentiment, with multiple firms downgrading MASI to neutral/hold and a consensus "Reduce" rating. Despite this selloff, institutional investors still hold approximately 85.96% of Masimo's stock, with other funds initiating or increasing their positions.
Apple Prevails in ITC Dispute with Masimo Over Watch Patents - News and Statistics
The U.S. International Trade Commission (ITC) has ruled in favor of Apple in a patent dispute with Masimo concerning blood-oxygen measurement technology in Apple Watches. The ITC declined to review a prior ruling that found Apple's redesigned watches do not infringe Masimo's patents, allowing Apple to continue offering the health feature. Masimo, owned by Danaher, still retains the right to appeal and has ongoing separate legal actions against Apple regarding patent and trade-secret infringement.
Apple Clears Major Legal Hurdle After U.S. Trade Tribunal Shuts Down Masimo’s Latest Watch Ban Attempt
The U.S. International Trade Commission (ITC) has ruled in favor of Apple, rejecting Masimo’s attempt to impose a new import ban on certain Apple Watch models. This decision follows a preliminary ruling in March that found Apple's redesigned smartwatches do not infringe Masimo's blood-oxygen measurement patents. Masimo, which had accused Apple of intellectual property theft, can appeal the ITC's decision.
Masimo (MASI) Secures $100M Contract Modification for Patient Monitoring Equipment
Masimo (MASI) has secured a significant contract modification worth up to $100 million for patient monitoring systems, extending its agreement with the U.S. military and federal agencies for another five years. While this ensures a steady revenue stream and reinforces Masimo's market position, concerns exist regarding its declining revenue growth and recent insider stock sales totaling $2.6 million. Investors are encouraged to consider these factors, alongside the company's strong GF Score™ of 87 and a high price-to-sales ratio, for a comprehensive evaluation.
Massachusetts Financial Services Co. MA Boosts Stock Position in Masimo Corporation $MASI
Massachusetts Financial Services Co. MA increased its stake in Masimo Corporation by 1.7% in the fourth quarter, now owning 4.96% of the company, valued at approximately $346.5 million. Despite this, analyst consensus for Masimo is a "Reduce" rating with a target price of $181.17, following several downgrades from research firms. The medical equipment provider has a market cap of $9.58 billion and is trading near its 12-month high.
Masimo stock price target raised to $180 by Jefferies on Danaher deal
Jefferies has increased its price target for Masimo Corp. (NASDAQ:MASI) shares to $180 from $168, maintaining a Hold rating, in anticipation of Danaher's acquisition of Masimo. The deal, valued at $9.9 billion or $180 per share, is expected to close in the second half of 2026 and implies a significant discount compared to Masimo's current market valuation. This news comes alongside Masimo's projected 9% revenue growth for 2025 and a recent downgrade by Raymond James due to the impending acquisition.
Masimo stock price target raised to $180 by Jefferies on Danaher deal
Jefferies has increased its price target for Masimo Corp. (NASDAQ:MASI) shares to $180 from $168, maintaining a Hold rating, in anticipation of Danaher's acquisition of Masimo. Danaher announced its intent to acquire Masimo for $9.9 billion, or $180 per share, with the deal expected to close in the latter half of 2026. This valuation suggests a relative discount compared to Masimo's current market valuation, and the stock is trading near its 52-week high.
31,641 Shares in Masimo Corporation $MASI Acquired by Tudor Investment Corp ET AL
Tudor Investment Corp ET AL recently acquired 31,641 shares of Masimo Corporation (NASDAQ:MASI) for approximately $4.67 million, representing 0.06% of the company. Institutional investors own about 85.96% of Masimo, which has a market cap of $9.58 billion and is trading near its 52-week high. Analyst sentiment for Masimo is largely "Reduce" with a consensus price target of $181.17, following several recent downgrades.
Masimo Corp Stock Operating Data
This GuruFocus article provides operating data for Masimo Corp (BSP:M2AS34), noting its current stock price, P/E ratio, P/B ratio, market cap, and enterprise value. It also flags five severe warning signs for the company. The article, part of Gurufocus.com's extensive financial analysis tools, emphasizes that operating data for Masimo Corp is not currently available.
Masimo Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Masimo Corporation - MASI
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Masimo Corporation (NasdaqGS: MASI) to Danaher Corporation (NYSE: DHR) for $180.00 per share in cash. The law firm is scrutinizing whether this offering price and the process leading to it are adequate, suspecting that the consideration may undervalue Masimo. KSF encourages Masimo shareholders who believe the transaction undervalues the company or wish to discuss their legal rights to contact them.
Wealth Enhancement Advisory Services LLC Raises Stake in Masimo Corporation $MASI
Wealth Enhancement Advisory Services LLC significantly increased its stake in Masimo Corporation (NASDAQ:MASI) by 483.7% in Q4, acquiring an additional 9,423 shares to own a total of 11,371 shares valued at approximately $1.56 million. Despite this, Masimo currently holds an average analyst rating of "Reduce" with a target price of $181.17, following several recent downgrades from financial institutions. The medical equipment provider has a market capitalization of $9.59 billion and is trading with a negative P/E ratio of -16.94.
Masimo agrees $10BN Danaher switch
Danaher, a biotechnology and diagnostics company, is set to acquire Masimo Corporation, known for its optical pulse oximetry devices, in a deal worth nearly $10 billion. Masimo will operate as a standalone business unit within Danaher's diagnostics segment, a move expected to strengthen its global reach and accelerate innovation in patient monitoring. The acquisition follows a period of significant change for Masimo, including a leadership change, sale of its non-healthcare business, and a patent infringement win against Apple.
Quinn Emanuel Disqualified from Masimo Board Fight with Founder
A California state court has disqualified Quinn Emanuel Urquhart & Sullivan LLP from representing Masimo Corp. directors in a lawsuit against former CEO Joe Kiani. The disqualification stems from the firm's prior representation of both Masimo and Kiani in an earlier case, without obtaining Kiani's informed consent to represent the company against him in subsequent litigation. This decision impacts one of several ongoing legal battles between the medical technology company and its founder.
Quinn Emanuel Disqualified from Masimo Board Fight with Founder
A California state court judge has disqualified Quinn Emanuel Urquhart & Sullivan LLP from representing Masimo Corp. directors in a lawsuit brought by its founder, Joe Kiani. The judge ruled that Masimo's board failed to obtain Kiani's informed consent for the law firm's dual representation in previous related litigation. This decision highlights the complexities of conflicts of interest in high-stakes corporate disputes and means Masimo will need to secure new legal counsel.
Masimo Corp Stock: Innovative Medical Tech Leader with Strong Growth Potential for North American In
Masimo Corp is highlighted as a leading innovator in noninvasive patient monitoring, offering robust growth potential for North American investors. The article details its core business model, technological leadership in pulse oximetry and advanced sensors, and strong market positioning against competitors. It also covers the company's financial health, innovation pipeline, and strategic outlook, while acknowledging risks inherent in the medtech industry.
Assenagon Asset Management S.A. Grows Stock Holdings in Masimo Corporation $MASI
Assenagon Asset Management S.A. significantly increased its stake in Masimo Corporation (NASDAQ:MASI) by 2,078.5% in the fourth quarter of the previous year. Other institutional investors, including Viking Global Investors LP and Squarepoint Ops LLC, also increased their exposure to Masimo. Despite increased institutional ownership, several analysts have downgraded Masimo to a "Hold" or "Sell" rating, with a consensus target price of $181.17.
Danaher to Acquire Masimo Diagnostics in $9.9B Deal
Danaher Corp. announced its acquisition of Masimo Corp. for $9.9 billion, including debt, in a deal set to significantly impact the global diagnostics sector. Danaher will pay $180 per share in cash, with Masimo operating as a standalone unit within Danaher's diagnostics segment post-acquisition. The transaction, expected to close in the second half of 2026, aims to integrate Masimo's patient monitoring technologies and expand its global reach.
The Vanguard Group discloses 0 shares in Masimo Corp (NASDAQ: MASI)
The Vanguard Group has filed an Amendment No. 12 to its Schedule 13G/A, reporting zero beneficial ownership of Masimo Corp (NASDAQ: MASI) common stock, equating to 0% of the company. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their ownership separately, as per SEC Release No. 34-39538. Previously, these subsidiaries' holdings were aggregated with The Vanguard Group.
Masimo Corporation $MASI Shares Sold by JPMorgan Chase & Co.
JPMorgan Chase & Co. decreased its holding in Masimo Corporation (NASDAQ:MASI) by 21.8% in the third quarter, selling 30,149 shares and retaining 107,941 shares valued at $15.93 million. Despite Masimo trading near its 52-week high, the company currently holds a "Hold" consensus rating from Wall Street analysts with an average price target of $181.17. The medical technology company, known for its noninvasive monitoring solutions, has a market capitalization of $9.5 billion and a negative P/E ratio, indicating ongoing losses.
Masimo Corporation (NASDAQ:MASI) Receives Average Recommendation of "Hold" from Brokerages
Masimo Corporation (NASDAQ:MASI) has received an average "Hold" recommendation from nine analysts, with an average 1-year price target of $181.17. Recent downgrades from firms like BTIG, Wolfe Research, and Piper Sandler suggest waning analyst enthusiasm, and the company's shares trade at $176.89 with a market cap of $9.5 billion. Institutional investors hold a significant portion of the company's stock, with some recent large acquisitions.
